Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.33)
# 961
Out of 5,170 analysts
68
Total ratings
53.19%
Success rate
15.1%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Neutral | $100 → $105 | $85.76 | +22.43% | 5 | Feb 3, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $13.50 | +48.15% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $72.68 | +4.57% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $7.61 | +83.97% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $126.59 | -21.00% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $18.81 | +64.81% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $18.38 | -51.03% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $44.80 | -26.34% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $117.61 | +61.55% | 6 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $25.26 | -24.78% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $299.57 | +30.19% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $48.74 | +12.84% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $89.08 | -38.26% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $111.75 | +43.18% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $470.21 | +42.49% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $4.75 | +321.05% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,190.49 | +17.60% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.40 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $33.63 | +167.62% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $190.11 | +42.02% | 4 | Dec 20, 2023 |
Revvity
Feb 3, 2026
Maintains: Neutral
Price Target: $100 → $105
Current: $85.76
Upside: +22.43%
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $13.50
Upside: +48.15%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $72.68
Upside: +4.57%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $7.61
Upside: +83.97%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $126.59
Upside: -21.00%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $18.81
Upside: +64.81%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $18.38
Upside: -51.03%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $44.80
Upside: -26.34%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $117.61
Upside: +61.55%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $25.26
Upside: -24.78%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $299.57
Upside: +30.19%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $48.74
Upside: +12.84%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $89.08
Upside: -38.26%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $111.75
Upside: +43.18%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $470.21
Upside: +42.49%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $4.75
Upside: +321.05%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,190.49
Upside: +17.60%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.40
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $33.63
Upside: +167.62%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $190.11
Upside: +42.02%